← Atlas Theme · spans 1 topics
Geopolitical competition drives the wholesale acceleration of early-stage trials.
The fear of ceding clinical and scientific leadership to foreign adversaries compels national health authorities to overhaul regulatory gateways and fast-track phase-one clinical protocols.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
HHS and FDA's "Operation Trialblazer": Accelerating Clinical Trials — Now with ARPA-H's SURPASS, STACK, COMMONS, and CINCH This line highlights how intense geopolitical competition from China is driving the U.S. executive to aggressively accelerate and streamline domestic early-stage clinical trial approvals.
Science & Health
FDA Launches Expedited IND Pilot Under Operation TrialBlazer — Applications Open Through October 30, 2026 The stated rationale for the expedited IND pilot is geopolitical fear of ceding early-stage trial leadership to foreign rivals.